Temodar® (temozolomide)

Last Review Date: July 15, 2019
Number: MG.MM.PH.170

Medical Guideline Disclaimer

All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth Services Company LLC, (“EmblemHealth”) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Temodar is an alkylating antineoplastic agent. Temodar undergoes rapid chemical conversion at physiologic pH to the active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is thought to be due primarily to methylation of DNA at the O6 and N7 positions of guanine. The formation of Omethylguanine inhibits DNA replication through errant repair of the methyladduct and causes cell death via stimulation of p53 and apoptosis. Temodar is cell-cycle non-specific; however, cell cycle arrest usually occurs between the G2- and M-phases. The combination of Temodar (temozolomide) and radiation therapy results in additive effects.

Length of Authorization

Coverage will be provided for 6 months and may be renewed.

Dosing Limits

Max Units (per dose and over time) [Medical Benefit]:
- 200 mg/m2/day

I. INITIAL APPROVAL CRITERIA

Temodar may be considered medically necessary if one of the below conditions are met AND use is consistent with the medical necessity criteria that follows:

- Patient age is ≥ 18 years old; AND
- Prescribed by or in consultation with an oncologist; AND
- Dose does not exceed 200 mg/m2/day; AND
- Patient has medical documentation for one of the following indications:
  1. Glioblastoma
  2. Anaplastic Astrocytoma
Limitations/Exclusions
Temodar is not considered medically necessary when any of the following selection criteria is met:

1) Disease progression while on Temodar (temozolimide).
2) Dosing exceeds single dose limit of 200 mg/m2/day.
3) Indications not supported by CMS recognized compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

II. RENEWAL CRITERIA

- Patient continues to meet INITIAL APPROVAL CRITERIA.
- Tumor response with disease stabilization or reduction of tumor size and spread.

Dosage/Administration

<table>
<thead>
<tr>
<th>Indication</th>
<th>Dose</th>
</tr>
</thead>
</table>
| Glioblastoma            | - **Concomitant phase:** 75 mg/m2 daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions) followed by maintenance Temodar for 6 cycles.  
                          | - **Maintenance phase:**  
                          |   Cycle 1: Four weeks after completing the Temodar+RT phase, Temodar is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.  
                          |   Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. |
| Anaplastic astrocytoma  | - Initial dose is 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle. |

Applicable Procedure Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9328</td>
<td>Injection, temozolomide, 1 mg, 1 billable unit = 1 mg</td>
</tr>
</tbody>
</table>

Applicable NDCs

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00085-1381-xx</td>
<td>Temodar single use vial; 100 mg powder for solution</td>
</tr>
</tbody>
</table>
Applicable Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10</th>
<th>ICD-10 Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C71.0 - C71.9</td>
<td>Malignant neoplasm of brain [intracranial ependymoma] [adult low-hyphengrade infiltrative supratentorial astrocytoma/oligodendroglioma] [adult medulloblastoma or supratentorial primitive neuroectodermal tumors (PNET)] [anaplastic gliomas] [glioblastoma]</td>
</tr>
<tr>
<td>C72.0 C72.9</td>
<td>Malignant neoplasm of central nervous system [anaplastic gliomas, glioblastoma, adult low-hyphengrade infiltrative supratentorial astrocytoma/oligodendroglioma (excluding pilocytic astrocytoma)]</td>
</tr>
</tbody>
</table>

References